Literature DB >> 28733702

Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Miodrag Dragoj1, Jasna Bankovic1, Evangelia Sereti2, Sofija Jovanovic Stojanov1, Konstantinos Dimas2, Milica Pesic1, Tijana Stankovic3.   

Abstract

Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. At the time of diagnosis, a large percentage of NSCLC patients have already developed metastasis, responsible for extremely high mortality rates. CXCR4 receptor and focal adhesion kinase (FAK) are known to regulate such invasive cancer behavior. Their expression is downregulated by p53 and PTEN tumor suppressors which are commonly co-inactivated in NSCLC patients and contribute to metastasis. Therefore, targeting CXCR4 or FAK seems to be a promising strategy in suppressing metastatic spread of p53/PTEN deficient NSCLCs. In this study, we first examined the invasive characteristics of NSCLC cells with suppressed p53 and PTEN activity using wound healing, gelatin degradation and invasion assays. Further, changes in the expression of CXCR4 and FAK were evaluated by RT-qPCR and Western Blot analysis. Finally, we tested the ability of CXCR4 and FAK inhibitors (WZ811 and PF-573228, respectively) to suppress the migratory and invasive potential of p53/PTEN deficient NSCLC cells, in vitro and in vivo using metastatic models of human NSCLC. Our results showed that cells with mutually inactive p53 and PTEN have significantly increased invasive potential associated with hyperactivation of CXCR4 and FAK signaling pathways. Treatments with WZ811 and PF-573228 inhibitors significantly reduced migratory and invasive capacity in vitro and showed a trend of improved survival in vivo. Accordingly, we demonstrated that p53/PTEN deficient NSCLCs have extremely invasive phenotype and provided a rationale for the use of CXCR4 or FAK inhibitors for the suppression of NSCLC dissemination.

Entities:  

Keywords:  CXCR4; FAK; Invasion; Non-small cell lung carcinoma; PTEN; p53

Mesh:

Substances:

Year:  2017        PMID: 28733702     DOI: 10.1007/s10637-017-0494-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  42 in total

1.  Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway.

Authors:  Jacquelyne S Poon; Robert Eves; Alan S Mak
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

2.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

3.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

4.  Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Authors:  S A Mehta; K W Christopherson; P Bhat-Nakshatri; R J Goulet; H E Broxmeyer; L Kopelovich; H Nakshatri
Journal:  Oncogene       Date:  2006-11-27       Impact factor: 9.867

5.  Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

Authors:  Maria V Guijarro; Sonika Dahiya; Laura S Danielson; Miguel F Segura; Frances M Vales-Lara; Silvia Menendez; Dorota Popiolek; Khushbakhat Mittal; Jian Jun Wei; Jiri Zavadil; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Eva Hernando
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307

6.  Inactivation of p53 and Pten promotes invasive bladder cancer.

Authors:  Anna M Puzio-Kuter; Mireia Castillo-Martin; Carolyn W Kinkade; Xi Wang; Tian Huai Shen; Tulio Matos; Michael M Shen; Carlos Cordon-Cardo; Cory Abate-Shen
Journal:  Genes Dev       Date:  2009-03-04       Impact factor: 11.361

7.  Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway.

Authors:  Hong Xia; Richard Seonghun Nho; Judy Kahm; Jill Kleidon; Craig A Henke
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

Review 8.  FAK and p53 protein interactions.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Anticancer Agents Med Chem       Date:  2011-09       Impact factor: 2.505

9.  BMP-2 up-regulates PTEN expression and induces apoptosis of pulmonary artery smooth muscle cells under hypoxia.

Authors:  Weifeng Pi; Xuejun Guo; Liping Su; Weiguo Xu
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

10.  PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Authors:  M Katie Conley-LaComb; Allen Saliganan; Pridvi Kandagatla; Yong Q Chen; Michael L Cher; Sreenivasa R Chinni
Journal:  Mol Cancer       Date:  2013-07-31       Impact factor: 27.401

View more
  1 in total

Review 1.  The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.

Authors:  Jin Zhou; Qian Yi; Liling Tang
Journal:  J Exp Clin Cancer Res       Date:  2019-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.